SHAREHOLDER ALERT: Investigation of Provention Bio Announced by Holzer & Holzer, LLC

Atlanta, Georgia--(Newsfile Corp. - July 6, 2021) -  Holzer & Holzer, LLC is investigating whether Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) complied with federal securities laws. On July 6, 2021, Provention announced the issuance of a Complete Response Letter ("CRL") by the FDA for the Company's Biologics License Application ("BLA") for the drug Teplizumab. Specifically, the FDA noted that a recent study "failed to show Pharmacokinetic comparability" and notified Provention that it must either demonstrate PK compatibility for Teplizumab or provide other data showing why PK compatibility is not necessary. After the Company's announcement, the price of Provention significantly dropped.

If you purchased shares of Provention stock and suffered a loss on that investment, you are encouraged to either contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer, Esq. is the attorney responsible for its content.

CONTACT:
Corey D. Holzer, Esq.
Joshua Karr, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com
jkarr@holzerlaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/89534